e-learning
resources
Paris 2018
Monday, 17.09.2018
Experimental research in pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).
J. Abu-Hanna (London, United Kingdom), J. Taanman (London, United Kingdom), D. Abraham (London, United Kingdom), L. Clapp (London, United Kingdom)
Source:
International Congress 2018 – Experimental research in pulmonary hypertension
Session:
Experimental research in pulmonary hypertension
Session type:
Thematic Poster
Number:
3059
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Abu-Hanna (London, United Kingdom), J. Taanman (London, United Kingdom), D. Abraham (London, United Kingdom), L. Clapp (London, United Kingdom). Impact of treprostinil on dynamin-related protein 1 (DRP1) and mitochondrial fragmentation in pulmonary arterial hypertension (PAH).. 3059
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
Homeodomain-interracting protein kinase 2 (HIPK2) in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Arterial hypertension (AH) and endothelial function (EF) in patients with COPD
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice
Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension
Year: 2009
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH)
Source: Eur Respir J 2003; 22: Suppl. 45, 270s
Year: 2003
Capillary lung volume (QC) and membrane conductance (DmCO) in patients with pulmonary hypertension: effects of tracleer
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD)
Source: Eur Respir J 2005; 26: Suppl. 49, 564s
Year: 2005
Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH)
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept